NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 13.5% in February

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 6,511 shares, a decline of 13.5% from the January 29th total of 7,529 shares. Based on an average daily volume of 1,762 shares, the days-to-cover ratio is currently 3.7 days. Based on an average daily volume of 1,762 shares, the days-to-cover ratio is currently 3.7 days.

NeuroSense Therapeutics Stock Performance

Shares of NRSNW stock remained flat at $0.21 during mid-day trading on Wednesday. 200 shares of the stock were exchanged, compared to its average volume of 1,578. NeuroSense Therapeutics has a 1 year low of $0.16 and a 1 year high of $1.00. The firm’s 50 day simple moving average is $0.28 and its 200-day simple moving average is $0.36.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.